EDAP Reports Third Quarter 2015 Financial Results and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
EDAP Reports Third Quarter 2015 Financial Results and Operational Update
  • Obtained FDA clearance for Ablatherm® HIFU in November
  • Received first four U.S. orders for Ablatherm
  • Record nine-month net sales of €20.5 million
  • HIFU treatment-driven revenue increased 41% year-over-year
  • Strong backlog for both lithotripsy and HIFU divisions entering Q4
  • First Focal One® Device sold in South America

LYON, France, Nov. 18, 2015 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq: EDAP ), the global leader in therapeutic ultrasound, today announced financial results for the third quarter ended September 30, 2015 and provided an update on recent strategic and operational highlights.

Marc Oczachowski, EDAP's Chief Executive Officer, stated, "Following the end of the third quarter, we achieved the most significant milestone in the Company's history with receipt of FDA clearance for Ablatherm HIFU. Bringing our HIFU technology to the U.S. market has been a key objective for several years, and this clearance is the result of the hard work and dedication of the entire EDAP team. We have already received Ablatherm Robotic HIFU orders from four U.S. urology Groups and academic centers, and numerous other inquiries regarding the product, which is indicative of the robust demand for HIFU among members of the U.S. urological community. We are initiating shipments of Ablatherm Robotic HIFU systems from our manufacturing facility in France this week, and we anticipate completing the installations very soon in key locations in the U.S.

"Our net sales for the first nine months of 2015 grew 3.3% over last year to a record €20.5 million on the strength of our lithotripsy business and procedure-driven HIFU revenues. Importantly, we have built a strong backlog which included 20 lithotripters and five HIFU devices as of the middle of the fourth quarter, giving us visibility into the end of the year and early 2016. Our business is clearly gaining momentum, and we believe that the FDA clearance of Ablatherm Robotic HIFU will provide a significant catalyst for future growth as we continue to ramp our commercial efforts in the U.S. We have established EDAP as the HIFU leader in Europe and other parts of the world, and I am confident that we can replicate that success in the United States."

Third Quarter 2015 Results

Total revenue for the third quarter of 2015 was EUR 6.4 million (USD 7.1 million), compared to EUR 6.9 million (USD 9.0 million) for the third quarter 2014, which included a EUR 0.5 million (USD 0.7 million) one-off revenue related to the licensing of a HIFU patent.

Total revenue in the HIFU business for this quarter was EUR 1.2 million (USD 1.3 million) compared to EUR 2.9 million (USD 3.9 million) for the third quarter 2014.

For the three months ended September 30, 2015, total revenue for the Lithotripsy division was EUR 5.2 million (USD 5.8 million), compared to EUR 4.0 million (USD 5.4 million), during the year ago period.

Gross profit for the third quarter 2015 was EUR 2.6 million (USD 2.9 million), compared to EUR 3.4 million (USD 4.4 million) for the year ago period. Gross profit margin on net sales was 40.2% in the third quarter of 2015, compared to 53.2% in the year ago period.

Operating expenses were EUR 2.8 million (USD 3.2 million) for the third quarter 2015, compared to EUR 3.1 million (USD 4.0 million) for the same period in 2014.

Operating loss for the third quarter 2015 was EUR 0.3 million (USD 0.3 million), compared with operating income of EUR 0.3 million (USD 0.4 million) in the third quarter of 2014, including the EUR 0.5 million (USD 0.7 million) one-off revenue for licensing of a HIFU patent)

Net loss for the third quarter 2015 was EUR 4.8 million (USD 5.4 million), or EUR 0.19 per diluted share, as compared to net income of EUR 6.6 million (USD 8.6 million), or EUR 0.26 per diluted share, in the year ago period. Net loss in the third quarter of 2015 included non-cash interest expense of EUR 4.5 million to adjust the accounting fair value of the outstanding warrants. This compares to non-cash interest income of EUR 6.5 million in the third quarter of 2014.

Results for the Nine Months Ended September 30, 2015

Total revenue for the first nine months of 2015 was EUR 20.5 million (USD 22.7 million), compared to EUR 20.3 million (USD 27.4 million) for the first nine months of 2014.

Gross profit for the period was EUR 8.5 million (USD 9.4 million) and gross profit margin was 41.5%, compared to 44.3 % in the year ago period.

Operating loss for the nine months of 2015 was EUR 1.1 million (USD 1.2 million), compared to EUR 0.7 million (USD 1.0 million) in the first nine months of 2014.

Net loss for nine months ended September 30, 2015 was EUR 6.8 million (USD 7.5 million), or EUR 0.27 per diluted share, as compared to net income of EUR 2.1 million (USD 2.9 million), or EUR 0.09 per diluted share, in the first nine months of 2014. Net loss in the first nine months of 2015 included a non-cash interest expense of EUR 5.9 million to adjust the accounting fair value of the outstanding warrants. This compares to non-cash interest income of EUR 3.0 million in the first nine months of 2014.

At September 30, 2015, cash and cash equivalents, including short-term treasury investments, were EUR 11.1 million (USD 12.4 million).

Conference Call

EDAP will hold a conference call on November 19, 2015 at 8:30 am. EST to discuss the results and provide an update on recent business developments, including the FDA clearance U.S. commercial launch of Ablatherm® HIFU. The dial-in numbers are 1-888-348-6419 in the U.S., and 1-412-902-4235 for international callers. The conference ID number for both is 10076376. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.edap-tms.com .

After the live event, the webcast will remain available on EDAP's website, www.edap-tms.com , through December 19, 2015. In addition, a dial-in replay of the call will be available until December 21, 2015. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers. Please use event passcode 10076376.

About EDAP TMS SA

EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and effective option for prostatic tissue ablation with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm-HIFU is approved for commercial distribution in Europe and some other countries including Mexico and Canada, and has received 510(k) clearance by the U.S. FDA. The Company also markets an innovative robot-assisted HIFU device, the Focal One®, dedicated to focal therapy of prostate cancer. Focal One® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and distributes medical equipment (the Sonolith® lithotripters' range) for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) in most countries including Canada and the U.S. For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com .

Forward-Looking Statements

In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.

EDAP TMS S.A.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(Amounts in thousands of Euros and U.S. Dollars, except per share data)
         
         
  Three Months Ended: Three Months Ended:
  September 30, September 30, September 30, September 30,
  2015 2014 2015 2014
  Euros Euros $US $US
Sales of goods 3,754 4,192 4,178 5,474
Net Sales of RPP and Leases 1,138 824 1,266 1,075
Sales of spare parts and Services 1,514 1,384 1,685 1,807
TOTAL NET SALES 6,406 6,400 7,129 8,356
Other revenues 1 511 1 667
TOTAL REVENUES 6,407 6,911 7,130 9,023
Cost of goods (2,262) (2,163) (2,517) (2,825)
Cost of RPP and Leases (648) (442) (721) (577)
Cost of spare parts & services (921) (899) (1,025) (1,174)
Cost of sales (3,830) (3,505) (4,262) (4,576)
         
GROSS PROFIT 2,578 3,406 2,868 4,447
Research & development expenses (612) (714) (682) (932)
Marketing & Sales expenses (1,518) (1,458) (1,689) (1,903)
G & A expenses (704) (895) (783) (1,169)
Total operating expenses (2,834) (3,067) (3,154) (4,004)
         
OPERATING PROFIT (LOSS) (257) 339 (286) 443
Interest (expense) income, net (4,460) 6,484 (4,963) 8,466
Currency exchange gains (loss), net (80) (245) (89) (320)
Other income (loss), net (2) (2) (2) (2)
         
INCOME (LOSS) BEFORE TAXES AND MINORITY INTEREST (4,798) 6,577 (5,340) 8,587
Income tax (expense) credit (31) (26) (35) (34)
         
NET INCOME (LOSS) (4,830) 6,551 (5,375) 8,554
Earnings per share – Basic (0.19) 0.26 (0.22) 0.34
Average number of shares used in computation of Basic EPS 24,972,752 24,859,267 24,972,752 24,859,267
Earnings per share – Diluted (0.19) 0.26 (0.22) 0.33
Average number of shares used in computation of Diluted EPS 24,972,752 25,623,929 24,972,752 25,623,929
         
NOTE:  Translated for convenience of the reader to U.S. dollars at the 2015 average three months noon buying rate of 1 Euro = 1.1128 USD, and 2014 average three months noon buying rate of 1 Euro = 1.3057 USD.
 
EDAP TMS S.A.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(Amounts in thousands of Euros and U.S. Dollars, except per share data)
         
  Nine Months Ended: Nine Months Ended:
  September 30, September 30, September 30, September 30,
  2015 2014 2015 2014
  Euros Euros $US $US
Sales of goods 12,857 12,948 14,275 17,474
Net Sales of RPP and Leases 3,258 2,846 3,617 3,841
Sales of spare parts and Services 4,344 4,002 4,822 5,401
TOTAL NET SALES 20,458 19,797 22,714 26,716
Other revenues 3 511 4 690
TOTAL REVENUES 20,461 20,308 22,717 27,406
Cost of goods (7,303) (7,322) (8,108) (9,881)
Cost of RPP and Leases (1,940) (1,583) (2,154) (2,137)
Cost of spare parts & services (2,730) (2,629) (3,030) (3,548)
Cost of sales (11,972) (11,535) (13,292) (15,566)
         
GROSS PROFIT 8,489 8,773 9,425 11,840
Research & development expenses (2,125) (2,332) (2,359) (3,147)
Marketing & Sales expenses (4,926) (4,521) (5,469) (6,102)
G & A expenses (2,534) (2,627) (2,813) (3,545)
Total operating expenses (9,585) (9,480) (10,641) (12,793)
         
OPERATING PROFIT (LOSS) (1,096) (707) (1,217) (954)
Interest (expense) income, net (5,804) 2,930 (6,444) 3,954
Currency exchange gains (loss), net 223 (29) 247 (39)
Other income (loss), net (5) (6) (5) (8)
         
INCOME (LOSS) BEFORE TAXES AND MINORITY INTEREST (6,682) 2,188 (7,419) 2,953
Income tax (expense) credit (100) (62) (112) (84)
         
NET INCOME (LOSS) (6,783) 2,126 (7,530) 2,869
Earnings per share – Basic (0.27) 0.09 (0.30) 0.12
Average number of shares used in computation of Basic EPS 24,942,689 23,157,314 24,942,689 23,157,314
Earnings per share – Diluted (0.27) 0.08 (0.30) 0.11
Average number of shares used in computation of Diluted EPS 24,942,689 25,296,513 24,942,689 25,296,513
         
         
NOTE:  Translated for convenience of the reader to U.S. dollars at the 2015 average nine months noon buying rate of 1 Euro = 1.1102USD, and 2014 average nine months noon buying rate of 1 Euro = 1. 3495USD.
 
EDAP TMS S.A.
CONSOLIDATED BALANCE SHEETS HIGHLIGHTS (Amounts in thousands of Euros and U.S. Dollars)
         
         
   Sept. 30,   June 30,   Sept. 30,  June 30, 
  2015 2015 2015 2015
   Euros  Euros  $US  $US
         
Cash, cash equivalents and short term investments  11,073 11,851 12,359 13,219
Total current assets 27,003 28,442 29,802 31,725
Total current liabilities 12,570 13,942 14,030 15,552
Shareholders' Equity  8,914 13,383 9,949 14,928
         
NOTE:  Translated for convenience of the reader to U.S. dollars at the noon buying rate of 1 Euro = 1.1162 USD on September 30, 2015 and at the noon buying rate of 1 Euro = 1.1154 USD, on June 30, 2015 
 
EDAP TMS S.A.
CONDENSED STATEMENTS OF OPERATIONS BY DIVISION
NINE MONTHS ENDED SEPTEMBER 30, 2015
(Amounts in thousands of Euros)
              Total After  
  HIFU Division   UDS Division   FDA Corporate Consolidation  
                 
Sales of goods 2,561   10,296       12,857  
Sales of RPPs & Leases 2,099   1,158       3,258  
Sales of spare parts & services 494   3,849       4,344  
TOTAL NET SALES 5,155   15,303       20,458  
                 
Other revenues 2   1       3  
                 
TOTAL REVENUES 5,157   15,305       20,461  
                 
GROSS PROFIT 2,826 55% 5,663 37%     8,489 42%
(% of Total Revenues)                
                 
Research & Development (983)   (674)   (468) -- (2,125)  
Total SG&A plus depreciation (2,146)   (4,318)   -- (996) (7,460)  
                 
OPERATING PROFIT (LOSS) (303)   671   (468) (996) (1,096)  

Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 72 Investors: Lee Roth The Ruth Group 646-536-7012

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 13

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Dawson Struggles With Q3 Losses Despite Growth Prospects

Updated Category News Views 25

Profit and loss dance around like a jittery stock, and Dawson Geophysical is feeling the heat this third quarter. Numbers are in, and we’re seeing a net loss of $5.2 million, translating to $0.17 per share—ouch. Not to mention a negative Adjusted EBITDA of $2 million. Compared to last year's hopes, that's a serious belly flop. Revenue Down, Hopes Up In a fetching...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 36

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 160

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Mining Equipment Market to Surge, Hitting $42.81B by 2033

Updated Category News Views 86

Forecasts on Market Growth: A Robust Climb Ahead Brace yourself because this mining equipment racket is ramping up like you wouldn't believe. Analysts are telling us the market's supposed to roar from a $28.42 billion check in 2026 to a jaw-dropping $42.81 billion come 2033. That's a 6.0% CAGR—a figure that'll catch the eye of anyone not sound asleep at the wheel....

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 254

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
SANY's Bold AI Showdown at bauma CHINA 2026

Updated Category News Views 0

SANY's Future Vision: AI Agents and Robotic Machinery The construction machinery game is about to get a whole lot smarter, if SANY has anything to say about it. They're rolling out their biggest show ever at bauma CHINA 2026, and the headline act? A fresh breed of AI agents and robotic machinery that promises to revolutionize the industry. Marking its 40-year legacy, SANY...

Continue Reading
RBC Grabs Top Honors for Sustainable Investing Leadership

Updated Category News Views 21

A New Feather in RBC's Cap RBC Wealth Management has racked up more accolades, crowned as the Best Private Bank in Canada and celebrated for its prowess in impact and sustainable investing on the global stage. These distinctions flew in courtesy of the PWM Global Private Banking Awards—a heavyweight recognition in the wealth management world. Award Winning Strategy in...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 86

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading

Top 5 Most Recently Viewed Articles

Choice Hotels Unveils Comprehensive Sustainability Efforts

Updated Category News Views 387

Choice Hotels International Launches 2024 Sustainability Report Choice Hotels International, Inc. (NYSE: CHH), a leading global lodging franchisor, has officially released its 2024 Sustainability Report, showcasing its ongoing commitment to environmental sustainability. The report highlights the company's innovative approaches to reducing its carbon footprint and...

Continue Reading
Revitalizing Communities Through Skilled Trades Initiatives

Updated Category News Views 157

Revitalizing Communities Through Skilled Trades Initiatives In an important moment for many towns across America that are striving for renewal, a new initiative has emerged to shine a light on the necessity of skilled trades. The campaign, titled Careers in Manufacturing, is aimed at highlighting how vital these trades are for both local economies and the workforce on the...

Continue Reading
Color Me Mine Celebrates Growth and Franchise Success

Updated Category News Views 344

Color Me Mine Achieves Remarkable Mid-Year Growth Color Me Mine, a leading paint-your-own pottery franchise, is excited to announce significant growth through its studio expansion and franchisee success. The brand is witnessing a thriving landscape of opportunities, fueled by enthusiastic franchise owners who are making their mark in various communities. Studio Expansion...

Continue Reading
Earnings Insights: Companies Set to Report Soon

Updated Category News Views 202

Upcoming Earnings Reports for Major Companies As the earnings season approaches, investors and analysts eagerly anticipate the financial results from several prominent companies. This article highlights some of the key players expected to announce their quarterly results. Companies Reporting Before the Market Opens UP Fintech Holding (TIGR) UP Fintech Holding is projected...

Continue Reading
Cogent Biosciences Shares Insights at Prestigious Healthcare Event

Updated Category News Views 207

Cogent Biosciences Highlights Participation in Major Healthcare Conference Cogent Biosciences, Inc. (Nasdaq: COGT), a pioneering biotechnology company, is ready to showcase its innovative approach to precision medicine at the highly regarded J.P. Morgan Healthcare Conference. Taking place in San Francisco, this annual event is a crucial platform for industry leaders to...

Continue Reading